Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,046.91
-4.33 (-0.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
40
41
Next >
Earnings Preview For Regeneron Pharmaceuticals
February 03, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
February 01, 2022
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.
Via
Benzinga
3 Biotech Stocks That Could Boom or Bust in Q1
February 01, 2022
The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future.
Via
InvestorPlace
5 Things To Expect This Week
January 31, 2022
While the "January effect" was rather disappointing, February kicks off with an important week ahead for many types of investors.
Via
InvestorPlace
Analyst Ratings For Regeneron Pharmaceuticals
January 31, 2022
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:
Via
Benzinga
Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use
January 28, 2022
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have
Via
Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
January 31, 2022
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.
Via
Benzinga
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
January 31, 2022
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a posi
Via
Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
January 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Promising Results Continue to Develop Optimism in Fight Against Cancers
January 27, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 27, 2021 – USA News Group – There’s plenty of optimism surrounding the major medical breakthroughs targeting multiple types...
Via
FinancialNewsMedia
A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Earnings, Fed Meeting
January 25, 2022
Pre-open movers U.S. stock futures traded mostly lower in early pre-market trade. The Dow Jones settled higher by around 100 points on Monday after tumbling more than 1,000 points...
Via
Benzinga
FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why
January 24, 2022
Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their...
Via
Benzinga
Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?
January 24, 2022
The demand for monoclonal antibody treatments to help in the recovery of COVID-19 patients has outpaced the supply, and this situation runs the risk of becoming more acute as...
Via
Benzinga
Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease
January 19, 2022
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in...
Via
Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
January 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)...
Via
Benzinga
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
January 19, 2022
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
Via
Benzinga
WHO Recommends Glaxo, Eli Lilly Drugs For COVID-19 Treatment Amid Omicron Surge
January 14, 2022
An expert panel at the World Health Organization (WHO) recommended the use of treatments developed by Eli Lilly And Co (NYSE: LLY) and GlaxoSmithKline Plc...
Via
Benzinga
Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares
January 13, 2022
Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year Connect Biopharma...
Via
Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
Why JPMorgan Is Among Rob Sechan's Top Picks For 2022
January 10, 2022
With the Federal Reserve having suggested that rates are likely headed higher this year, financials have been an area of focus for investors.&...
Via
Benzinga
Why This Pfizer, Regeneron Analyst Has Contrasting Recommendations For The COVID Stock Plays
January 05, 2022
An analyst at BofA Securities on Wednesday shared a pair trade idea in the large-cap pharma space. The Biopharma Analyst:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
January 05, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE:
Via
Benzinga
Market Briefing For Wednesday, Jan. 5
January 05, 2022
Rising interest rates have yet to spark overt action by the Fed nor yet to cool-off the hot real estate market. However, the Nasdaq was hit hard, presumably as the 10-year rallied.
Via
Talk Markets
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
January 04, 2022
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,...
Via
FinancialNewsMedia
Exposures
COVID-19
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 3, 2022
January 03, 2022
Upgrades For nVent Electric PLC (NYSE:NVT), Vertica...
Via
Benzinga
Healthcare Stocks Are Winners And Provide Diversification To Your Portfolio
December 30, 2021
As we have written their year many times speculative small cap biotechs have not done well in 2021 since they peaked in February.
Via
Talk Markets
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
December 29, 2021
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The...
Via
Benzinga
3 Cathie Wood Stocks To Buy On The Dip
December 25, 2021
Institutional investor Cathie Wood gained popularity after her ETFs generated big gains last year. Wood asserted recently that her stocks are poised for long-term gains. Hence, we think investing in...
Via
Talk Markets
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
December 22, 2021
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.
Via
Talk Markets
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.